Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0959-8049(94)90084-1PMID 8155393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278

  2004cited by this paper
• Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil

  2004cited by this paper
• Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil.

  1992cited by this paper
• Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.

  1992cited by this paper
• Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.

  1992cited by this paper
• The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.

  1991cited by this paper
• Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing.

  1991cited by this paper
• Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study.

  1991cited by this paper
• Clinical pharmacokinetics of carboplatin.

  1991cited by this paper
• Clinical Pharmacokinetics of Carboplatin

  1991cited by this paper
• Mechanism of diethyldithiocarbamate modulation of murine bone marrow toxicity.

  1990cited by this paper
• Cisplatin dose intensity.

  1989cited by this paper
• European experience with ifosfamide in non-small cell lung cancer.

  1989cited by this paper
• Clinical trials of WR-2721 and cis-platinum.

  1989cited by this paper
• Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug.

  1988cited by this paper
• An assay for growth of mouse bone marrow cells in microtiter liquid culture using the tetrazolium salt MTT, and its application to studies of myelopoiesis.

  1988cited by this paper
• Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine-(1,1-cyclobutanedicarboxylato)platinum(II).

  1988cited by this paper
• Can WR-2721 be improved upon?

  1988cited by this paper
• Pharmacokinetics of WR-2721.

  1988cited by this paper
• Assessment of cytotoxic injury to bone marrow.

  1986cited by this paper
• Use of MTT colorimetric assay to measure cell activation.

  1986cited by this paper
• The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukaemia.

  1986cited by this paper
• Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.

  1985cited by this paper
• Food systems: perspectives on demographics and affluence, food supply and consumption.

  1983cited by this paper
• Effects of cisplatin on different haemopoietic progenitor cells in mice.

  1982cited by this paper
• A growth factor produced by WEHI-3 cells for murine high proliferative potential GM-progenitor colony forming cells.

  1982cited by this paper
• Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721.

  1981cited by this paper
• MURINE MONONUCLEAR PHAGOCYTES FROM BONE MARROW

  1981cited by this paper
• Methods for Studying Mononuclear Phagocytes

  1981cited by this paper
• Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.

  1980cited by this paper
• Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.

  1980cited by this paper
• Factors from mouse tissues stimulating colony growth of mouse bone marrow cells in vitro.

  1971cited by this paper

• Molecular Influence of the ATM Protein in the Treatment of Human Cells with Different Radioprotective Drugs: Comparisons between Antioxidative and Pro-Episkevic Strategies

  2023cites this paper
• The effects of radioprotectant and potential antioxidant agent amifostine on the structure and dynamics of DPPC and DPPG liposomes.

  2019cites this paper
• Clinical Status and Optimal Use of Amifostine Review

  2017cites this paper
• Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

  2016cites this paper
• Clinical and Preclinical Modulation of Chemotherapy-Induced Toxicity in Patients with Cancer

  2012cites this paper
• Amifostine

  2012cites this paper
• Radiation-induced chronic oxidative renal damage can be reduced by amifostine

  2012cites this paper
• Amifostine

  2012cites this paper
• Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

  2012cites this paper
• RADIATION-INDUCED CHRONIC-OXIDATIVE RENAL DAMAGE CAN BE REDUCED BY AMIFOSTINE

  2011cites this paper
• The role of sulfur in platinum anticancer chemotherapy.

  2007cites this paper
• Amifostine—Antioxidant Drug in Anticancer Therapy

  2006cites this paper
• Effects of amifostine on glycerol-pretreated rabbit kidneys.

  2005cites this paper
• Peripheral neuropathy

  2005cites this paper
• L-Carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC)

  2005cites this paper
• Induction of caspase 3 activity, bcl-2 bax and p65 gene expression modulation in human acute promyelocytic leukemia HL-60 cells by doxorubicin with amifostine.

  2005cites this paper
• Cytoprotection in acute myelogenous leukemia (AML) therapy.

  2004cites this paper
• WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

  2004cites this paper
• The effect of cytoprotective agents in platinum anticancer therapy.

  2004cites this paper
• Amifostine: is there evidence of tumor protection?

  2003cites this paper
• Induction of caspase 3 and modulation of some apoptotic genes in human acute promyelocytic leukemia HL-60 cells by carboplatin with amifostine.

  2003cites this paper
• Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.

  2003cites this paper
• Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment

  2003cites this paper
• Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies.

  2003cites this paper
• The Cytoprotective Aminothiol WR1065 Activates p53 through a Non-genotoxic Signaling Pathway Involving c-Jun N-terminal Kinase*

  2003cites this paper
• Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.

  2003cites this paper
• Enhancement of fotemustine (Muphoran®) cytotoxicity by amifostine in malignant melanoma cell lines

  2002cites this paper
• Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.

  2002cites this paper
• Amifostine in clinical oncology: current use and future applications

  2002cites this paper
• BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.

  2002cites this paper
• Amifostine: chemotherapeutic and radiotherapeutic protective effects

  2001cites this paper
• Has the outlook improved for amifostine as a clinical radioprotector?

  2000cites this paper
• Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line.

  2000cites this paper
• Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.

  2000cites this paper
• Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations.

  2000cites this paper
• Bone marrow purging by photodynamic treatment in children with acute leukemia: cytoprotective action of amifostine.

  2000cites this paper
• The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway

  2000cites this paper
• Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.

  1999cites this paper
• Clinical status and optimal use of amifostine.

  1999cites this paper
• High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma

  1999cites this paper
• Future development of amifostine as a radioprotectant.

  1999cites this paper
• Microvessel density and endothelial cell proliferation after amifostine (Ethyol) administration in vivo.

  1999cites this paper
• The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.

  1999cites this paper
• The potential of amifostine: from cytoprotectant to therapeutic agent.

  1999cites this paper
• Amifostine (WR2721) for dose escalation in marrow-ablative treatment of leukaemia.

  1999cites this paper
• Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.

  1999cites this paper
• Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.

  1999cites this paper
• A Risk-Benefit Assessment of Amifostine in Cytoprotection

  1999cites this paper
• Effect of amifostine (Ethyol®) on the development of extraembryonic blood vessels in chick embryos

  1999cites this paper
• Fluoropyrimidines as Antifolate Drugs

  1999cites this paper
• The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

  1999cites this paper
• The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines.

  1999cites this paper
• Amifostine modulation of bleomycin-induced lung injury in rodents.

  1999cites this paper
• Combined treatment of stage IV melanoma patients with amifostine and fotemustine — a pilot study

  1998cites this paper
• Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.

  1998cites this paper
• Protective effects of the thiophosphate amifostine (WR 2721) and a lazaroid (U83836E) on lipid peroxidation in endothelial cells during hypoxia/reoxygenation.

  1998cites this paper
• Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).

  1998cites this paper
• Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.

  1998cites this paper
• Amifostin

  1997cites this paper
• Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro

  1997cites this paper
• Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors

  1997cites this paper
• Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.

  1997cites this paper
• Pharmacokinetics of amifostine and its metabolites in patients.

  1997cites this paper
• Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.

  1997cites this paper
• Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.

  1997cites this paper
• Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.

  1997cites this paper
• Amifostine does not alter the antitumor activity of cisplatin in a pre‐clinical model of testicular cancer

  1996cites this paper
• Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.

  1996cites this paper
• The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).

  1996cites this paper
• Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.

  1996cites this paper
• Amifostine and chemotherapy-related thrombocytopenia.

  1996cites this paper
• [Amifostine: current and future applications in cytoprotection].

  1996cites this paper
• Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.

  1996cites this paper
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

  1996cites this paper
• Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy.

  1996cites this paper
• Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient

  1996cites this paper
• Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.

  1996cites this paper
• Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.

  1996cites this paper
• Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.

  1996cites this paper
• Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.

  1995cites this paper
• Cardioprotective potency of the radical scavenger S-2-(3 aminopropylamino) ethylphosphorothioic acid in the post-ischaemic rat heart

  1995cites this paper
• Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma.

  1995cites this paper
• Review : Amifostine and other chemoprotective agents in cancer chemotherapy: A brief review

  1995cites this paper
• Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

  1995cites this paper
• Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.

  1994cites this paper